## (19) World Intellectual Property Organization

International Bureau



# 

(43) International Publication Date 7 October 2004 (07.10.2004)

**PCT** 

### (10) International Publication Number WO 2004/084813 A3

- (51) International Patent Classification7: C07D 241/02, 401/00, 403/00, 405/00, 409/00, 411/00, 413/00, 417/00, 419/00
- (21) International Application Number:

PCT/US2004/008301

- (22) International Filing Date: 18 March 2004 (18.03.2004)
- (25) Filing Language:

English

(26) Publication Language:

**English** 

(30) Priority Data: 60/456,872

21 March 2003 (21.03.2003) US

- (71) Applicant (for all designated States except US): **BEECHAM** CORPORATION **SMITHKLINE** [US/US]; One Franklin Plaza, Philadelphia, PA 19101 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ALBERTI. Michael, John [US/US]; c/o GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). DREWRY, David, Harold [US/US]; c/o GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). MILLER, David, Drysdale [GB/GB]; c/o GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). BAMBOROUGH, Paul [GB/GB]; c/o GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).

- (74) Agents: LEVY, David, J. et al.; GlaxoSmithKline, Corporate Intellectual Property Dept., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO. CR. CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### **Published:**

with international search report

(88) Date of publication of the international search report: 17 February 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL COMPOUNDS

(57) Abstract: The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity.



#### TENT COOPERATION TREATY



## From the INTERNATIONAL SEARCHING AUTHORITY

To: DAVID J. LEVY	PCT			
GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY DEPT. FIVE MOORE DRIVE. PO BOX 13398 RESEARCH TRIANGLE PARK, NC 27709	NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION			
	(PCT Rule 44.1)			
	Date of mailing (day/month/year) 17 NOV 2004			
Applicant's or agent's file reference PR60143WO	FOR FURTHER ACTION See paragraphs 1 and 4 below			
International application No. PCT/US04/08301	International filing date (day/month/year) 18 March 2004 (18.03.2004)			
Applicant SMITHKLINE BEECHAM CORPORATION				
1. The applicant is hereby notified that the international search report and the written opinion of the International Searching Authority have been established and are transmitted herewith.				
Filing of amendments and statement under Article 19:  The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):				
When? The time limit for filing such amendments is normally two months from the date of transmittal of the international search report.				
Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes 1211 Geneva 20, Switzerland, Facsimile No.: +41 22 740 14 35				
For more detailed instructions, see the notes on the a	ccompanying sheet.			
2. The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.				
3. With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:				
the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.				
no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.				
4. Reminders				
Shortly after the expiration of 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.				
The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international				

examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

preliminary examination report has been or is to be established. These comments would also be made available to the public but not

Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary

before the expiration of 30 months from the priority date.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide,

Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Telephone No. (571) 272-1600

Authorized officer

Facsimile No. (703)305-3230 Form PCT/ISA/220 (January 2004)

(See notes on accompanying sheet)



# **PCT**

### INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference PR60143WO	FOR FURTHER ACTION	see Form PCT/ISA/220 as well as, where applicable, item 5 below.					
International application No. PCT/US04/08301	International filing date (day) 18 March 2004 (18.03.2004)	/month/year)	(Earliest) Priority Date (day/month/year) 21 March 2003 (21.03.2003)				
Applicant SMITHKLINE BEECHAM CORPORATION							
	transmitted to the Internation	nal Bureau.					
language in which it was filed, un  The international s furnished to this Authori	aless otherwise indicated under search was carried out on the b ty (Rule 23.1(b)).	this item. asis of a transla	is of the international application in the				
2. Certain claims were found u 3. Unity of invention is lacking 4. With regard to the title, the text is approved as submit	unsearchable (See Box No. II) g (See Box No. III)		ne international application, see Box No. I.				
5. With regard to the abstract, the text is approved as submit the text has been established, may, within one month from the date	according to Rule 38.2(b), by	this Authority a I search report,	s it appears in Box No. IV. The applicant submit comments to this Authority.				
	pplicant. uthority, because the applicant	failed to sugges	-				
b. none of the figures is to be pu	thority, because this figure be blished with the abstract.	tter characterize	s the invention.				

Form PCT/ISA/210 (first sheet) (January 2004)



International application No.

PCT/US04/08301

A. CLASSIFICATION OF SUBJECT MATTER						
IPC(7) : C07D 241/02, 401/00, 403/00, 405/00, 409/00, 411/00, 413/00, 417/00, 419/00						
	US CL : 544/357, 405					
According to	According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIEL	DS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) U.S.: 544/357, 405						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN: Registry (structure search) and Caplus (answer set from Registry cross-referenced)						
C. DOC	UMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.			
P,X	WO 03/066629 A2 (VERTEX PHARMACEUTIC. 2003 (14.08.2003), page 52, scheme XVI.	ALS INCORPORATED) 14 August	1			
	·					
		İ				
	-					
Further	documents are listed in the continuation of Box C.	See patent family annex.	****			
<del></del>	pecial categories of cited documents:	"T" later document published after the intern	ational filing date or priority			
"A" document	defining the general state of the art which is not considered to be arr relevance	date and not in conflict with the applicat principle or theory underlying the invent	ion but cited to understand the			
"E" earlier app	olication or patent published on or after the international filing date	"X" document of particular relevance; the cl considered novel or cannot be considere	nimed invention cannot be d to involve an inventive step			
"L" document	which may throw doubts on priority claim(s) or which is cited to	when the document is taken alone	·			
establish ti specified)	he publication date of another citation or other special reason (as	"Y" document of particular relevance; the cl- considered to involve an inventive step v	when the document is			
"O" document	referring to an oral disclosure, use, exhibition or other means	combined with one or more other such d being obvious to a person skilled in the a	ocuments, such combination ut			
"P" document priority da	published prior to the international filing date but later than the ue claimed	"&" document member of the same patent far	nily			
Date of the ac	ctual completion of the international search	Date of mailing of the international searce	h report			
13 October 20	004 (13.10.2004)	<b>17 NO</b> V 2004				
Name and ma	iling address of the ISA/US	Authorized officer	1 0			
	Mail Stop PCT, Atm: ISA/US Commissioner for Patents P.O. Box 1450  Addition 22d officer  Zachary C. Tucker  T. Rebullo for					
	missioner for Patents Box 1450	2. Tuesder ( 1: 10000	- P			
Alexandria. Virginia 22313-1450 Telephone No. (571) 272-1600						
гасѕише No	. (703)305-3230		1			

Form PCT/ISA/210 (second sheet) (January 2004)